Legend Biotech (LEGN) is trading up at $18.77 (+1.10%), as of the latest quote. It operates in the Health Care sector.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $49.1M | $60.0M | $75.0M | $68.8M | $117.0M | $285.1M | $627.2M | $1.03B |
| Growth (year over year) | — | +22.1% | +25.0% | −8.2% | +70.0% | +143.7% | +120.0% | +64.0% |
| Gross profit | — | — | $75.0M | $68.8M | $51.6M | $140.9M | $410.8M | $631.8M |
| Gross margin | — | — | 100.0% | 100.0% | 44.1% | 49.4% | 65.5% | 61.4% |
| Operating income | — | — | — | — | — | −$528.1M | −$309.5M | −$136.5M |
| Operating margin | — | — | — | — | — | −185.2% | −49.3% | −13.3% |
| Net income | −$2.78M | −$101.6M | −$266.4M | −$403.6M | −$446.3M | −$518.3M | −$177.0M | −$296.8M |
| Net margin | −5.7% | −169.4% | −355.2% | −586.4% | −381.5% | −181.8% | −28.2% | −28.8% |
| EPS (diluted) | −$0.01 | −$0.51 | −$1.13 | −$1.43 | −$1.40 | −$1.47 | −$0.48 | −$0.81 |
| Balance sheet | ||||||||
| Cash and equivalents | $210.2M | $83.4M | $455.7M | $688.9M | $786.0M | $1.28B | $286.7M | $901.9M |
| Total assets | — | $292.6M | $722.1M | $1.12B | $1.33B | $1.85B | $1.67B | $1.73B |
| Total liabilities | — | $141.3M | $124.3M | $353.5M | $586.7M | $597.2M | $629.6M | $731.6M |
| Shareholders' equity | $252.9M | $151.3M | $597.8M | $765.9M | $744.3M | $1.25B | $1.04B | $1.00B |
| Cash flow | ||||||||
| Operating cash flow | $307.7M | −$83.1M | −$223.0M | −$198.5M | −$201.3M | −$393.3M | −$144.0M | −$100.2M |
| Capital expenditure | $21.0M | $26.8M | $26.3M | $42.2M | $20.9M | $20.1M | $14.1M | $28.6M |
| Free cash flow | $286.7M | −$109.8M | −$249.3M | −$240.7M | −$222.2M | −$413.4M | −$158.1M | −$128.8M |
| Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $94.0M | $186.5M | $160.2M | $186.5M | $9.44M | $35.3M | $10.5M | — |
| Growth (year over year) | +158.7% | +154.4% | +66.9% | +134.7% | −90.0% | −81.1% | −93.4% | — |
| Gross profit | $44.9M | $141.2M | $107.7M | $117.1M | −$60.1M | −$59.5M | −$102.8M | — |
| Gross margin | 47.8% | 75.7% | 67.2% | 62.8% | −636.4% | −168.4% | −978.8% | — |
| Operating income | — | — | −$70.4M | −$79.3M | — | — | −$43.5M | — |
| Operating margin | — | — | −43.9% | −42.5% | — | — | −413.9% | — |
| Net income | −$59.8M | −$18.2M | −$125.3M | $26.3M | −$100.9M | −$125.4M | −$39.7M | — |
| Net margin | −63.6% | −9.8% | −78.2% | 14.1% | −1069.3% | −354.8% | −378.0% | — |
| EPS (diluted) | −$0.16 | −$0.05 | −$0.34 | $0.07 | −$0.27 | −$0.34 | −$0.11 | — |
| Balance sheet | ||||||||
| Cash and equivalents | $897.6M | $201.3M | $459.3M | $286.7M | $441.7M | $266.6M | $278.9M | $901.9M |
| Total assets | $1.78B | $1.80B | $1.74B | $1.67B | $1.62B | $1.69B | $1.71B | $1.73B |
| Total liabilities | $611.0M | $639.2M | $619.7M | $629.6M | $597.9M | $654.4M | $701.7M | $731.6M |
| Shareholders' equity | $1.16B | $1.16B | $1.12B | $1.04B | $1.02B | $1.04B | $1.01B | $1.00B |
| Cash flow | ||||||||
| Operating cash flow | $15.5M | −$1.65M | −$75.8M | −$82.0M | −$103.8M | −$13.0M | $28.8M | — |
| Capital expenditure | $6.24M | $3.42M | $2.06M | $2.37M | $2.00M | $9.22M | $5.00M | — |
| Free cash flow | $9.28M | −$5.07M | −$77.9M | −$84.4M | −$105.8M | −$22.3M | $23.8M | — |
From Legend Biotech's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Legend Biotech in our feed yet.